CLINICAL TRIALS PROFILE FOR DESLORATADINE

All Clinical Trials for DESLORATADINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00160537 ↗	POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)	Completed	UCB Pharma	Phase 4	2005-05-01	Comparative study on clinical efficacy and safety of levocetirizine and desloratadine as measured by the subject's satisfaction/dissatisfaction after one week of treatment
NCT00160589 ↗	LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)	Completed	UCB Pharma	Phase 4	2005-04-01	Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)
NCT00264303 ↗	CUTE (Chronic Urticaria Treatment Evaluation)	Completed	UCB Pharma	Phase 4	2005-12-01	A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity score over the first week of treatment
NCT00311844 ↗	A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)	Completed	Merck Sharp & Dohme Corp.	Phase 4	2005-03-01	This study was a double-blind, placebo-controlled, cross-over, single-center study of desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal allergic rhinoconjunctivitis. This study was performed to examine the effects of desloratadine compared with placebo, on the signs and symptoms of allergic conjunctivitis induced by direct conjunctival challenges with a previously identified sensitizing antigen, in the eyes of a subject known to be sensitive to the antigen.
NCT00346606 ↗	The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria	Unknown status	Lotus Pharmaceutical	Phase 4	2006-01-01	Objective: To compare the efficacy of desloratadine 5mg (Denosin®) and levocetirizine 5mg (Xyzal®) once daily in the treatment of patients with CIU over 6 weeks. Trial design: Randomized, Double-Blind, Active-Controlled, Parallel-Group Study. Primary end point: To evaluate the change in average AM/PM reflective pruritus score from baseline recorded in the subjects' diaries during the first two weeks of the treatment. Secondary Objectives: To assess the efficacy and safety of desloratadine 5mg (Denosin®) and levocetirizine 5mg (Xyzal®) once daily in the treatment of subjects with CIU over 6 weeks.
NCT00359138 ↗	The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)	Completed	Merck Sharp & Dohme Corp.	Phase 4	2006-02-01	This is a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single center study in subjects with positive histamine skin prick test and a positive RadioAllergoSorbent Test (RAST) (class > 2) to one of the tested standardized allergenic extracts: tree pollen, cat dander, house dust mite, or a mixture of five grass pollens. Subjects will be randomized to desloratadine 5 mg once daily, levocetirizine 5mg once daily, or placebo once daily for 8 days of treatment followed by 11 days of skin testing after discontinuation of the antihistamine treatment phase. The duration of the suppressive effects of desloratadine on cutaneous allergen-induced wheal and flare responses after discontinuation of a one-week treatment will be established.
NCT00405964 ↗	Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-09-01	This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis (PER)

Clinical Trial Conditions for DESLORATADINE

Condition Name

Condition Name for DESLORATADINE
Intervention	Trials
Urticaria	12
Allergic Rhinitis	10
Seasonal Allergic Rhinitis	9
Chronic Idiopathic Urticaria	5

Condition MeSH

Condition MeSH for DESLORATADINE
Intervention	Trials
Rhinitis	28
Rhinitis, Allergic	27
Urticaria	19
Chronic Urticaria	13

Clinical Trial Locations for DESLORATADINE

Trials by Country

Trials by Country for DESLORATADINE
Location	Trials
United States	8
Germany	6
Canada	5
Brazil	5
China	3

Trials by US State

Trials by US State for DESLORATADINE
Location	Trials
Florida	5
New Jersey	2
Maryland	1

Clinical Trial Progress for DESLORATADINE

Clinical Trial Phase

Clinical Trial Phase for DESLORATADINE
Clinical Trial Phase	Trials
Phase 4	26
Phase 3	22
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for DESLORATADINE
Clinical Trial Phase	Trials
Completed	58
Unknown status	3
Terminated	3

Clinical Trial Sponsors for DESLORATADINE

Sponsor Name

Sponsor Name for DESLORATADINE
Sponsor	Trials
Merck Sharp & Dohme Corp.	32
Dr. Reddy's Laboratories Limited	6
UCB Pharma	4

Sponsor Type

Sponsor Type for DESLORATADINE
Sponsor	Trials
Industry	56
Other	15
NIH	1

DESLORATADINE Market Analysis and Financial Projection

Desloratadine: Clinical Trials, Market Analysis, and Projections

Introduction to Desloratadine

Desloratadine is a second-generation antihistamine widely used to treat various allergic conditions, including seasonal and perennial allergic rhinitis, and chronic idiopathic urticaria (hives). It is known for its non-sedative properties, making it a preferred choice for managing chronic allergies without impairing daily productivity.

Clinical Trials and Efficacy

Perennial Allergic Rhinitis

Clinical trials have demonstrated the efficacy and safety of desloratadine in treating perennial allergic rhinitis. A multicenter, randomized, placebo-controlled study involving 676 patients showed that desloratadine rapidly reduced symptoms of perennial allergic rhinitis. The medication consistently diminished symptoms over a 4-week treatment period, with improvements observed in both nasal and nonnasal symptoms such as rhinorrhea, itching, sneezing, and postnasal drip[1].

Chronic Idiopathic Urticaria

Desloratadine has also been effective in alleviating the burden of chronic idiopathic urticaria. Clinical trials have shown significant improvements in symptoms, with desloratadine reducing the severity of hives and associated discomfort[3].

Safety Profile

The safety profile of desloratadine is favorable, with adverse events similar to those of the placebo group in clinical trials. Common adverse events include headache, viral infection, pharyngitis, and upper respiratory tract infection, but these are not significantly different from the placebo group. Notably, desloratadine does not cause somnolence or significant cardiovascular effects, even at doses nine times the clinical dose[1][3].

Market Analysis

Current Market Size and Projection

The global desloratadine market was valued at approximately USD 1.2 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.2% through 2030. Another estimate suggests the market size will reach $1,048 million by 2027, growing at a CAGR of 5.6% from 2022 to 2027[2][5].

Market Drivers

Several factors are driving the growth of the desloratadine market:

• Increasing Allergy Prevalence: Rising cases of allergic rhinitis and other allergic conditions are driving the demand for effective treatments like desloratadine.
• Advancements in Formulations: Innovations such as extended-release tablets, oral dissolvable tablets, and liquid forms are enhancing patient compliance and treatment outcomes.
• Digital Health Integration: The use of mobile health applications and wearable devices to track allergy symptoms and medication adherence is improving patient management and treatment efficacy[2].
• Expanding Global Reach: Emerging markets in Asia-Pacific and Latin America are contributing significantly to the market growth due to economic growth, increased healthcare access, and rising awareness of allergy treatments[2][5].

Market Segmentation

The desloratadine market can be segmented in several ways:

• By Distribution Channel: The market is segmented into offline and online retail. While the offline segment currently dominates, the online segment is expected to grow faster due to discounts, cashback, and membership offers[5].
• By Geography: North America currently holds a dominant share, but the Asia-Pacific region is expected to offer lucrative growth opportunities due to its evolving health infrastructure and growing medical awareness[5].

Combination Therapies and Strategic Partnerships

The introduction of desloratadine in combination with other therapeutic agents is gaining popularity, offering synergistic effects and comprehensive relief from multiple allergy symptoms. Pharmaceutical companies are forming strategic partnerships to advance desloratadine research and development, focusing on optimizing formulations and exploring new therapeutic applications[2].

Innovations and Future Trends

Enhanced Formulations

Recent innovations include the launch of extended-release tablets, oral dissolvable tablets, and liquid forms of desloratadine. These formulations aim to improve patient compliance and treatment outcomes by providing more convenient dosing schedules and prolonged therapeutic effects[2].

Digital Health Technologies

The integration of digital health technologies, such as mobile health applications and wearable devices, is revolutionizing the management of allergies. These tools provide real-time data and personalized recommendations, empowering patients to manage their allergies more effectively[2].

Emerging Markets

Emerging markets in Asia-Pacific and Latin America are becoming significant contributors to the desloratadine market. Economic growth, increased healthcare access, and rising awareness of allergy treatments in these regions are driving market expansion[2][5].

Key Takeaways

• Efficacy and Safety: Desloratadine is effective and safe in treating perennial allergic rhinitis and chronic idiopathic urticaria, with a favorable safety profile.
• Market Growth: The global desloratadine market is projected to grow significantly, driven by increasing allergy prevalence, advancements in formulations, and digital health integration.
• Innovations: Enhanced formulations and the integration of digital health technologies are improving treatment outcomes and patient compliance.
• Geographical Expansion: Emerging markets in Asia-Pacific and Latin America offer lucrative growth opportunities.

FAQs

1. What is desloratadine used for?

Desloratadine is an antihistamine used to relieve symptoms of allergies such as sneezing, runny nose, itchy eyes, and chronic urticaria (hives)[2].

2. How does desloratadine differ from first-generation antihistamines?

Desloratadine is a non-sedative second-generation antihistamine, unlike first-generation antihistamines which can cause drowsiness[2].

3. What are the common adverse events associated with desloratadine?

Common adverse events include headache, viral infection, pharyngitis, and upper respiratory tract infection, but these are not significantly different from the placebo group[1][3].

4. How is the desloratadine market segmented?

The market is segmented by distribution channel (offline and online retail) and geography (North America, Asia-Pacific, Europe, etc.)[5].

5. What are the key drivers of the desloratadine market growth?

Key drivers include increasing allergy prevalence, advancements in formulations, digital health integration, and expanding global reach, particularly in emerging markets[2][5].

Sources

1. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. PubMed.
2. Desloratadine Market Dynamics: How Innovations and Expanding Demand Are Reshaping Allergy Treatments. Market Research Intellect.
3. Desloratadine Tablets. Health Canada.
4. EU Clinical Trials Register: Desloratadine. EU Clinical Trials Register.
5. Desloratadine Market - Forecast (2024 - 2030). IndustryARC.